CN117257914B - Application of glutathione in preparation of medicines for preventing or treating silkworm nuclear polyhedrosis virus diseases - Google Patents
Application of glutathione in preparation of medicines for preventing or treating silkworm nuclear polyhedrosis virus diseases Download PDFInfo
- Publication number
- CN117257914B CN117257914B CN202311457695.1A CN202311457695A CN117257914B CN 117257914 B CN117257914 B CN 117257914B CN 202311457695 A CN202311457695 A CN 202311457695A CN 117257914 B CN117257914 B CN 117257914B
- Authority
- CN
- China
- Prior art keywords
- glutathione
- silkworm
- nuclear polyhedrosis
- polyhedrosis virus
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title claims abstract description 98
- 229960003180 glutathione Drugs 0.000 title claims abstract description 48
- 108010024636 Glutathione Proteins 0.000 title claims abstract description 47
- 241000255789 Bombyx mori Species 0.000 title claims abstract description 40
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 229940079593 drug Drugs 0.000 title abstract description 5
- 201000010099 disease Diseases 0.000 title description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 6
- 238000002360 preparation method Methods 0.000 title description 3
- 230000010076 replication Effects 0.000 claims abstract description 11
- 241000409811 Bombyx mori nucleopolyhedrovirus Species 0.000 claims abstract description 10
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 208000015181 infectious disease Diseases 0.000 claims abstract description 5
- 230000009385 viral infection Effects 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 10
- 238000011160 research Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 21
- 238000001514 detection method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000000234 capsid Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108010053070 Glutathione Disulfide Proteins 0.000 description 3
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- WMYLYYNMCFINGV-CKCBUVOCSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O.OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O WMYLYYNMCFINGV-CKCBUVOCSA-N 0.000 description 2
- 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000034303 cell budding Effects 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 241000534000 Berula erecta Species 0.000 description 1
- 241000722713 Carcharodon carcharias Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- -1 n Species 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses application of glutathione in medicines for treating or preventing silkworm nuclear polyhedrosis virus, and researches show that the small peptide glutathione of the silkworm can effectively inhibit replication of the silkworm nuclear polyhedrosis virus (BmNPV) in silkworm cells, so that the glutathione can be used for inhibiting replication of the virus in the silkworm cells and the silkworm bodies through proper concentration and medicine adding time, and a new thought is provided for preventing BmNPV infection of the silkworm.
Description
Technical Field
The invention belongs to the field of agricultural biology, and particularly relates to an inhibition effect of Glutathione (GSH) on silkworm nuclear polyhedrosis virus (BmNPV) and an application thereof in preventing and treating silkworm nuclear polyhedrosis virus diseases.
Background
Glutathione (Glutathione) is a tripeptide consisting of 3 amino acid residues of glutamic acid, cysteine, glycine, and is often abbreviated as GSH because the thiol group (SH) on cysteine is a reactive group of Glutathione. Glutathione has both oxidized and reduced forms, and is often abbreviated GSSG because oxidized glutathione is formed from two GSHs by sulfhydryl dehydrogenation. Reduced glutathione is the predominant form of presence in cells, typically accounting for over 95% of total glutathione. The glutathione can help to maintain normal immune system function, has the functions of antioxidation and detoxification, can be used as a medicine and a base material of functional foods, and can be widely applied to the functional foods such as aging delay, immunity enhancement, tumor resistance and the like. In addition, glutathione has been shown to inhibit replication of a variety of viruses, such as human type I herpes simplex virus (HSV-1), dengue Virus (DV), tobacco Mosaic Virus (TMV), influenza virus (influenza virus), and the like.
The silkworm has important economic value as a silk-producing insect. The silkworm nuclear polyhedrosis virus particles are in a rod shape and consist of capsids, nucleus pulposus in the capsids and tunica outside the capsids. The nucleocapsid (capsid + nucleus) of the present virus, after formation within the nucleus, acquires the envelope in two forms, forming two types of virions, one nucleocapsid released into the cytoplasm by budding of the cytoplasmic membrane, called budding virus, and one nucleocapsid by acquisition of the envelope in the nucleus of the host cell, the envelope of which has a lipid bilayer structure, the virions being embedded in protein crystalline inclusions, called polyhedrin-derived virions. Silkworm nuclear polyhedrosis virus infected silkworm diseases are also called blood type sepsis, all ages of silkworms can occur, the occurrence of the silkworm diseases is the greatest from middle 5 years to before and after aging, the later period of the silkworm diseases is characterized by body-white, link swelling, mania crawling, body wall breakage and pus discharge and death. The silkworm nuclear polyhedrosis virus (BmNPV) causes great economic loss to the silkworm industry every year. So far, there is no effective method for prevention and treatment. Therefore, the research has important significance on the medicines for inhibiting the silkworm nuclear polyhedrosis virus.
Disclosure of Invention
In view of the above, the present invention aims to provide an application of Glutathione (Glutathione) in preparing a medicament for treating or preventing silkworm nuclear polyhedrosis virus.
In order to achieve the above purpose, the present invention provides the following technical solutions:
application of glutathione in preparing medicine for treating silkworm nuclear polyhedrosis virus infection is provided. Preferably, the effective concentration of glutathione is 5mM-10mM.
Application of glutathione in preparing medicine for preventing silkworm nuclear polyhedrosis virus infection is provided.
In the invention, the medicine also comprises pharmaceutically acceptable auxiliary materials.
In the invention, the pharmaceutical dosage form can be various pharmaceutically practical dosage forms, preferably granules and liquid preparations.
The invention discloses an application of glutathione in preparing medicines for inhibiting silkworm nuclear polyhedrosis virus, which can inhibit the replication of the glutathione in cells by reasonably utilizing the glutathione resisting the silkworm nuclear polyhedrosis virus, and can be mixed in the food of the silkworm for eating to play a therapeutic role when infection occurs; or the feed can be fed by adding glutathione 24 hours before virus infection, so as to inhibit BmNPV proliferation and prevent infection.
Advantageous effects
The invention provides a new thought for the treatment of nuclear polyhedrosis virus infection of silkworms and lays a foundation for the prevention and treatment of virus infection in silkworm production.
The glutathione used in the invention is the small peptide existing in the host cell, and has good safety and good control effect. Glutathione is low in price, safe and nontoxic.
Drawings
FIG. 1 shows cell viability assays after addition of different concentrations of glutathione;
FIG. 2 is a graph showing the detection of glutathione content in virus-infected cells by glutathione treatment;
FIG. 3 shows the detection of the viral gene VP39 that is affected by different concentrations of glutathione treatment on BmNPV proliferation in cells;
FIG. 4 shows the detection of the viral protein VP39 that is affected by different concentrations of glutathione treatment on BmNPV proliferation in cells;
FIG. 5 is a fluorescent observation of the effect of different concentrations of glutathione treatment on proliferation of BmNPV in cells.
Detailed Description
The technical scheme of the invention is clearly and completely described below with reference to the accompanying drawings and the specific embodiments. So that those skilled in the art may better understand the present invention and be able to practice it, the examples are not intended to limit it.
Glutathione in the present invention is purchased from Shanghai Biotechnology (cat# A100399); CCK-8 is purchased from white shark (cat# BS 350A); fluorescent quantitative detection kit NovoStart SYBR qPCR SuperMix kit was purchased from an offshore protein (cat# E096); proteinase K was purchased from Beijing radix (cat# RT 403); anti-beta-Tubulin antibodies, the coat Anti-Rabbit IgG antibodies, the coat Anti-Mouse IgG antibodies were purchased from Beijing full gold (accession numbers: HC101; HS101; HS201, respectively); anti-VP39 antisera was delegated to Hangzhou Huaan; GSH and GSSG detection kits were purchased from Shanghai Biyun (cat# S0053).
Example 1: the glutathione is utilized to inhibit the replication of the silkworm nuclear polyhedrosis virus in vitro,
this example 1 provides a test method for inhibiting replication of silkworm nuclear polyhedrosis virus in vitro using glutathione:
when the cytotoxicity detection of the glutathione is carried out, the silkworm BmN cells with good growth state are taken, plated one day in advance, 10mM glutathione storage solutions with different volumes are respectively added into different holes in the next day, the final concentration of the 10mM glutathione storage solutions is 1, 2, 5, 10, 20 and 50 mu M respectively, the control is a culture medium, and the culture is continued for 24 hours. Next, the activity of the cells was measured using CCK-8 assay kit, and as shown in FIG. 1, glutathione had no effect on the activity of the cells within 10mM.
When the intracellular glutathione content is detected, silkworm BmN cells with good growth state are taken and plated one day in advance, the first group is normal cells, the second group is cells added with 10 mu L of virus particle BV only, the third group is cells added with 10 mu L of virus particle BV and 10mM glutathione, and after the cells are continuously cultured for 48 hours, the intracellular glutathione content is detected by collecting the cells, and the result is shown in figure 2. The results show that: intracellular glutathione levels were reduced after viral infection compared to the control group, while the additional addition of glutathione was able to restore glutathione levels to normal levels in the infected cells.
When in-vitro virus infection experiments are carried out, silkworm BmN cells with good growth state are taken, plated in advance one day, glutathione with different concentrations is added the next day, the culture medium with the same volume is used as a contrast, after the culture is continued for 24 hours, EGFP-BV virus particles with the same volume and fluorescent markers are added, after 48 hours of infection, virus fluorescence is observed first, and then the cells are harvested to detect the replication condition of the virus.
In this example, the method for detecting replication of nuclear polyhedrosis virus by fluorescence quantitative PCR is to extract total DNA of samples respectively by using genome extraction reagents, design fluorescence quantitative primers according to nuclear polyhedrosis virus genes, and use silkworm GAPDH genes as internal references, wherein the primers used for fluorescence quantitative use are as follows:
BmNPV-VP39 Forward：5’-ACTTTTCATGATGTCACTGC-3’
BmNPV-VP39 Reverse：5’-AGTACTTGCAAATCGACACG-3’
Bm-GAPDH Forward：5’-CATTCCGCGTCCCTGTTGCTAAT-3’
Bm-GAPDH Reverse：5’-GCTGCCTCCTTGACCTTTTGC-3’
preparing a PCR reaction System by the extracted DNA and the fluorescent quantitative primer according to a fluorescent quantitative detection kit NovoStart SYBR qPCR SuperMix kit instruction book, and preheating for 30 seconds by using a fluorescent quantitative PCR instrument CFX96 Real-Time System (Berle) under the reaction condition of 94 ℃; denaturation at 94℃for 10 seconds, annealing at 60℃for 30 seconds and fluorescence collection were performed for 40 cycles, and the detection result was passed through 2 -ΔΔCT The method was used for analysis.
In this example, the method for detecting replication of nuclear polyhedrosis virus by western blot is to separate the total protein of the cell sample by SDS-PAGE, transfer it to PVDF membrane, incubate with different antibodies, and finally color-develop and detect the expression level of the protein on the membrane.
The results are shown in fig. 3, 4 and 5. Compared with the control group, the glutathione with proper concentration can inhibit the proliferation of virus in silkworm body, and the inhibiting effect is enhanced with the increase of concentration.
The foregoing is a further elaboration of the present invention in connection with the detailed description, and it is not intended that the invention be limited to the specific embodiments shown, but rather that a number of simple deductions or substitutions be made by one of ordinary skill in the art without departing from the spirit of the invention, should be considered as falling within the scope of the invention as defined in the appended claims.
Claims (6)
1. The application of glutathione in preparing medicine for preventing silkworm from infecting nuclear polyhedrosis virus is characterized in that the glutathione inhibits the replication of the silkworm nuclear polyhedrosis virus.
2. The application of glutathione in preparing medicine for treating silkworm infection nuclear polyhedrosis virus is characterized in that the glutathione inhibits the replication of the silkworm nuclear polyhedrosis virus.
3. The use according to claim 1 or 2, wherein the effective concentration of glutathione to inhibit the bombyx mori nuclear polyhedrosis virus is 5-mM-10 mM.
4. The use according to claim 1, wherein glutathione is used for inhibiting the bombyx mori nuclear polyhedrosis virus for a period of time of 24 hours before the virus infection.
5. The use according to claim 1 or 2, wherein the medicament further comprises pharmaceutically acceptable excipients.
6. The use according to claim 1 or 2, wherein the pharmaceutical dosage form is a solid granule, a liquid formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311457695.1A CN117257914B (en) | 2023-11-03 | 2023-11-03 | Application of glutathione in preparation of medicines for preventing or treating silkworm nuclear polyhedrosis virus diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311457695.1A CN117257914B (en) | 2023-11-03 | 2023-11-03 | Application of glutathione in preparation of medicines for preventing or treating silkworm nuclear polyhedrosis virus diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117257914A CN117257914A (en) | 2023-12-22 |
| CN117257914B true CN117257914B (en) | 2024-03-22 |
Family
ID=89204669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311457695.1A Active CN117257914B (en) | 2023-11-03 | 2023-11-03 | Application of glutathione in preparation of medicines for preventing or treating silkworm nuclear polyhedrosis virus diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117257914B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000031132A1 (en) * | 1998-11-24 | 2000-06-02 | Kyowa Hakko Kogyo Co., Ltd. | Novel polypeptide |
| CN104027347A (en) * | 2014-05-26 | 2014-09-10 | 江苏科技大学 | Application of methyl-beta-cyclodextrin in preparation of medicines for preventing and controlling BmNPV from infecting silkworm cells |
| CN116478262A (en) * | 2022-09-28 | 2023-07-25 | 西南大学 | Application of RACK1 in resisting silkworm nuclear polyhedrosis virus BmNPV |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITTO20031048A1 (en) * | 2003-12-30 | 2005-06-30 | Umberto Benatti | GLUTATORY DERIVATIVES AND THEIR USE FOR THE TREATMENT OF VIRAL DISEASES. |
-
2023
- 2023-11-03 CN CN202311457695.1A patent/CN117257914B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000031132A1 (en) * | 1998-11-24 | 2000-06-02 | Kyowa Hakko Kogyo Co., Ltd. | Novel polypeptide |
| CN104027347A (en) * | 2014-05-26 | 2014-09-10 | 江苏科技大学 | Application of methyl-beta-cyclodextrin in preparation of medicines for preventing and controlling BmNPV from infecting silkworm cells |
| CN116478262A (en) * | 2022-09-28 | 2023-07-25 | 西南大学 | Application of RACK1 in resisting silkworm nuclear polyhedrosis virus BmNPV |
Non-Patent Citations (3)
| Title |
|---|
| Quantitative label-free proteomic analysis reveals differentially expressed proteins in the digestive juice of resistant versus susceptible silkworm strains and their predicted impacts on BmNPV infection;Shang-zhi Zhang 等;Journal of Proteomics;20191011;第210卷;第1-14页 * |
| 家蚕Ｇ蛋白γ1亚基（ＢｍＧγ1）的克隆及其谷胱甘肽硫 转移酶融合蛋白的表达与纯化;章玉萍 等;蚕业科学;20081231;第34卷(第4期);第627-633页 * |
| 日本血吸虫28kD GST基因在家蚕细胞 和幼虫中的表达;田愕 等;生物化学与生物物理学报;19970131;第29卷(第1期);第33-39页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117257914A (en) | 2023-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103710359A (en) | Reoviruses having modified sequences | |
| CN111035631B (en) | Application of calcium lactate in preparation of medicine for preventing and treating spring viremia of carp virus infection | |
| CN113082049B (en) | New application of potassium iodide or composition containing potassium iodide in preparation of drugs for treating African swine fever | |
| US10155947B2 (en) | Method for inhibiting Ebola virus via miRNA | |
| CN112791084A (en) | New application of ML-60218 in preventing or treating African swine fever | |
| CN117257914B (en) | Application of glutathione in preparation of medicines for preventing or treating silkworm nuclear polyhedrosis virus diseases | |
| CN113398219A (en) | Application of exocarpium citri rubrum extract for preparing medicine for inhibiting human coronavirus infection | |
| CN106038695B (en) | Use of avocado extract, avocadol B and (2R,4R) -1,2, 4-trihydroxyheptadeca-16-alkyne, and health food containing avocado extract | |
| Nishijima et al. | Detection of anti-feline infectious peritonitis virus activity of a Chinese herb extract using geneLEAD VIII, a fully automated nucleic acid extraction/quantitative PCR testing system | |
| CN102337250A (en) | Infectious bovine rhinotracheitis virus strain and preparation method and application thereof | |
| CN111171144B (en) | Preparation and application of antibody for resisting porcine epidemic diarrhea virus | |
| CN117695295B (en) | Application of pyridoxal phosphate in preparation of medicines for preventing or treating silkworm nuclear polyhedrosis virus diseases | |
| KR102644990B1 (en) | Antiviral composition against foot-and-mouth disease virus | |
| CN118203596B (en) | Application of licorice polysaccharide in preparing medicine for resisting cat infectious peritonitis virus | |
| CN114712342B (en) | Application of lithospermic acid in preparation of anti-influenza virus drugs | |
| CN111166737B (en) | Application of mangiferin | |
| CN117379432B (en) | Application of compound or medicinal salt thereof in preparing medicament for treating and preventing diseases caused by porcine pseudorabies virus | |
| CN113274406B (en) | New application of manganese chloride or composition containing manganese chloride in preparation of drugs for treating African swine fever | |
| CN112516150B (en) | Application of tripterygium triterpenic acid in preparation of medicine for preventing and treating white spot syndrome virus | |
| CN108524514B (en) | Application of reserpine in preparation of medicine for resisting porcine epidemic diarrhea virus | |
| CN116115734A (en) | Application of GSDME gene encoding protein in preparation of colon cancer treatment drugs | |
| CN118490669A (en) | Application of virus receptor binding agent in fish antiviral | |
| CN118340752A (en) | Application of curcumin in preparation of medicines for resisting nervous necrosis virus | |
| CN117085010A (en) | Application of ezetimibe in preparation of medicines for preventing and/or treating porcine epidemic diarrhea virus infectious diseases | |
| Yin et al. | Potential effect of p-casomorphin-7 on lymphocyte and tlr\nf-kb signaling pathway in intestinal mucosa of aged mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |